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Abstract
Low bone mineral density (BMD) as a risk factor for fractures has been a long-
standing concern in phenylketonuria (PKU). It is hypothesised that the disease itself
or the dietary treatment might lead to a low BMD. Previous studies show con-
flicting results of BMD in PKU due to differences in age, techniques to assess
BMD and criteria used. To assess the prevalence of low BMD and define possible
risk factors in a large number of adult, early treated PKU (ETPKU) patients.
European centres were invited for a survey, collecting retrospective data including
results of dual-energy X-ray absorptiometry (DXA) scans of adult ETPKU patients.
BMD of 183 adult ETPKU patients aged 18-46 (median age 28, all females
premenopausal) years was lower than in the general population at most skeletal
sites but the frequency of low BMD (Z-score ≤−2) was at maximum 5.5%. No risk
factors for low BMD in PKU patients could be identified. Low BMD occurs only
Abbreviations: BMD, bone mineral density; BMI, body mass index; DXA, dual-energy X-ray absorptiometry; ETPKU, early treated PKU; FNBMD, femoral
neck bone mineral density; ISCD, International Society for Clinical Densitometry; LBMD, lumbar bone mineral density; PAH, phenylalanine hydroxylase;
Phe, phenylalanine; PKU, phenylketonuria; RBMD, radius bone mineral density; TBMD, total body bone mineral density; TFBMD, total proximal femur
bone mineral density.
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in a small subset of PKU patients. DXA scans should be considered for well con-
trolled patients from age 35-40 years and up and on indication in those PKU
patients considered to be at increased risk for fractures.
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1 | INTRODUCTION
Phenylketonuria (PKU, ORPHA79254, MIM 261600) is an
inborn error of metabolism in which deficiency of the
enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1)
causes high phenylalanine (Phe) concentrations which lead
to intellectual disability if left untreated. Since the 1960's-
1970's, patients are detected early by newborn screening
and treatment with a Phe-restricted diet is started immedi-
ately. This results in a near normal outcome of develop-
ment. However, as the first early treated PKU (ETPKU)
patients become older, new concerns about long term con-
sequences of PKU and its treatment arise.1-4 Most attention
is given to the neurocognitive issues and psychosocial func-
tioning, but also bone health has been a long-standing con-
cern in PKU patients.3,4 It is hypothesised that the Phe
restricted diet or the disease itself might lead to a low bone
mineral density (BMD) in PKU. However, previous studies
show conflicting results due to differences in assessing
BMD and different criteria for defining low BMD.4-13 Fur-
thermore, most studies included a small number of patients.
In 2015, the meta-analysis by Demirdas and colleagues
showed that low BMD for chronological age, defined as a
Z-score ≤−2 (in agreement with the International Society
for Clinical Densitometry (ISCD) criteria) is expected in
approximately 10% of ETPKU patients.8,14 However, most
of the studies included in this meta-analysis focused on
BMD in both adult and paediatric patients, with only one
small study focusing solely on adult patients.15 Including
the results of BMD in paediatric patients might distort the
information about adult patients for several reasons. Factors
like bone development, growth, puberty, and body compo-
sition all affect (assessment of) BMD.16,17 In addition peak
bone mass is attained during late adolescence/early adult-
hood.18 Therefore, there is a need for the assessment of
BMD in a large cohort of adult ETPKU patients. Insight in
BMD of adults with PKU will determine further need for
follow up.
The aim of the presented multicentre survey study was to
collect retrospective data for assessment of the prevalence of
low BMD and to define possible risk factors for low BMD
in a large number of adult, ETPKU patients.
2 | METHODS
Seventeen European centres specialised in treating adult PKU
patients were invited to participate in a survey study collecting
retrospective data of individual adult ETPKU patients. Partici-
pating centres were asked to complete a questionnaire for all
early treated (start treatment <4 weeks of age), adult
(≥18 years) PKU patients of whom data of dual-energy X-ray
absorptiometry (DXA) was available. Exclusion criteria were
chronic conditions affecting bone health; chronic malabsorp-
tion disease, chronical use of steroids (>5 mg of prednisolone
daily for 3 months or longer), rheumatoid arthritis, immobil-
ity, hypogonadism, organ transplantation, type 1 diabetes
mellitus, thyroid disorders, chronic obstructive pulmonary dis-
ease as well as a postmenopausal state.14,18-20
The questionnaire included deindentified data involving
demographics, anthropometrics, diet, and supplements, mean
Phe (μmol/L) during the year before the recent DXA scan (one
centre included mean Phe of the 2 years before the recent DXA
scan), use of sapropterin dichloride, low vitamin D concentration
(defined as 25-OH vitamin D <50 nmol/L),21 (number of) frac-
tures, smoking or ex-smoker status, and alcohol consumption.
The (most recent) DXA results in Z-score were collected
for different skeletal sites; lumbar (LBMD), femoral neck
(FNBMD), total proximal femur (TFBMD), radius (RBMD),
and total body (TBMD). According to the ISCD criteria
Z-scores and not T-scores were used as the studied patients
involved premenopausal women and men <50 years of age.
A BMD Z-score ≤−2 SD was defined as below the expected
range for age (low BMD), and a Z-score >−2 was defined as
within the expected range for age.14
Data was collected in Castor EDC, a good clinical prac-
tice compliant data management system.
The medical ethics committee of the Amsterdam UMC,
AMC, Amsterdam, The Netherlands, confirmed that for this
survey study collecting retrospective data the Medical
Research Involving Human Subjects Act (WMO) did not
apply and informed consent was not required. This article
does not contain any studies with human or animal subjects
performed by any of the authors.
2.1 | Statistical analysis
Sample size calculation by the Lehr's formula22 revealed that
a sample size of at least 80 patients (after correction for
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unequal sized groups23) was sufficient to yield 80% power
to detect a difference of at least 7.6% in prevalence of low
BMD in ETPKU patients compared to the general popula-
tion with a type I error of 5%, based on the available data by
Demirdas et al.8
Analysis was performed using IBM SPSS statistics 23. Nor-
mally distributed data was compared by parametric tests (one
sample t test or unpaired t test), non-normally distributed data
was analysed by non-parametric tests (Wilcoxon signed rank
test or Mann-Whitney U test). Categorical data was analysed
TABLE 1 Characteristic of included patients
Continuous data N Median (range)
Age at data collection (years) 183 32 (19-53)
Age most recent DXA (years) 183 28 (18-46)
Recent BMI 179 24.9 (17.5-49)
Mean Phe the year before the most recent DXA
(μmol/L)
168 775 (61-1816)
Categorical data N %
Gender 183 Male 42
Disease severity based on Phe before treatment1,2 87 Classic PKU (Phe ≥1200) 68
Mild PKU (Phe >600 and <1200) 22
Mild hyperphe (Phe ≤600) 10
Natural protein intake 183 Missing or not adherent to a diet 16
Severe protein restriction (≤10 g/day) 24
Moderate protein restriction (>10 to 20 g/day) 21
Mild protein restriction (>20 to 40 g/day) 16
Protein intake > recommended intake (>40 g/day)a 23
Sapropterin dichloride use 167 Yes 14
No (not tested or unresponsive) 86
Low vitamin D concentration (25-OH vitamin D
<50 nmol/L)
173 Yes 32
Vitamin D supplementation 162 Yes 26
Calcium supplementation 161 Yes 19
(ex) Smoker status 106 Yes 22
Alcohol consumption (on average >2 units/day) 106 Yes 26
Abbreviations: BMI, body mass index; DXA, dual-energy X-ray absorptiometry; PKU, phenylketonuria.
aAn amount of >40 g was based on the safe amount of protein of 0.8 g/kg/day according to FAO/WHO/UNU with some patients weighing around 50 kg.
TABLE 2 Mean, median BMD Z-scores, and % low BMD measured at several skeletal sites
Skeletal site N Mean Z-score (+1 SD) Median Z-score (range)
Compared to
general populationb Number (%) low BMDc
Lumbar 181 −0.527 (+ 1.030) −0.600 (−2.8;2.6) P < .0000* 10 (5.5)
Femoral neck 111 −0.324 (+ 0.913) −0.400 (−2.4;2.0) P = .0003* 4 (3.6)
Total proximal femur 128 −0.262 (+ 0.925) −0.300 (−2.4;2.9) P = .002* 2 (1.6)
Radius 55 −0.298 (+ 1.176) −0.400 (−3.2;1.8) P = .065 3 (6)
Total bodya 88 - −0.400 (−5.9;2.7) P = .002* 4 (5)
Abbreviation: BMD, bone mineral density.
aNot normally distributed.
bMean Z-score= 0.
cDefined as Z-score ≤−2.14
*Significantly different from the general population (P < .05) after post-hoc adjustment of P value by Bonferroni method (multiplying P value by the number of
tests (5)).






























































































































































































































































































































































































































































































































































































































































































































254 LUBOUT ET AL.
by a χ2or Fishers Exact test. In case of multiple hypothesis test-
ing, a post-hoc analysis was done by the Bonferroni method
(multiplying P-value by the number of tests). A P-value <.05
was considered statistically significant.22,24,25
In case of multiple DXA scans in one patient, the most
recent was selected for analysis. Mean BMD (Z-score) was
assessed for the different skeletal sites and compared to the
expected mean Z-score (0) in the general population. Fre-
quency of low BMD was calculated.
The spine and hip region are the sites of preference to
measure BMD.14,19 Several possible risk factors were taken
into consideration when comparing patients with a low
BMD at the spine level and those with a BMD within nor-
mal range. They included; gender, age at time most recent
DXA, recent Body Mass Index, natural protein intake, use
of calcium and vitamin D supplements, use of sapropterin
dichloride, mean Phe the year before the recent DXA scan,
low vitamin D concentration, and life style factors (smoking
and alcohol consumption).4,7,10-13,18,19,26 Not for all patients
with a statement of normal diet the exact amount of natural
protein intake was available. Before statistical analysis was
performed, natural protein intake was categorised according
to the following groups; (a) missing or not adherent to a diet,
(b) severe protein restriction (≤10 g/day), (c) moderate pro-
tein restriction (>10 to 20 g/day), (d) mild protein restriction
(>20 to 40 g/day), (e) protein intake > recommended intake
(>40 g/day). An amount of >40 g was based on the safe
amount of protein of 0.8 g/kg/day according to FAO/WHO/
UNU with some patients weighing around 50 kg.3
Frequency of fractures was compared to the estimated age-
standardised fracture prevalence as described for England.27
3 | RESULTS
A total of 8 (out of 17 invited) European metabolic centres,
situated in France, Poland, Spain, the Netherlands, and the
United Kingdom, participated in the study. Among 9 other
centres, 3 could not participate for various reasons and 6 did
not respond.
For most centres all of the patients were included. In
2 centres not all patients could be included within the inclu-
sion period. Therefore, a random selection of patients was
made to prevent bias (selection on alphabetical order or
order of appearance at the outpatient clinic).
Data of a total of 216 patients were received. Thirty-three
patients were excluded for the following reasons: no early
treatment N = 11, most recent DXA scan <age 18 years
N = 11, or significant co-morbidity that might affect BMD
N = 11, resulting in a total number of 183 to be analysed.
The characteristics of the included patients are presented
in Table 1. Based on the Phe concentration before diagnosis
and/or the natural protein intake, most of the included
patients have severe PAH deficiency. The mean individual
Phe concentration the year before the recent DXA was per-
formed showed a wide range, with a median for the group of
775 μmol/L.2-4
Most BMD results were available for the spinal level.
Mean BMD Z-scores were significantly lower in PKU
patients compared to the reference population for all skeletal
sites except the radius. The lowest result was seen for the
spine with a mean Z score of −0.527 (+1.030). Frequency of
low BMD (defined as a Z-score ≤−2) was observed in 1.6%-
5.5% with the maximum being observed at the spinal level
(Table 2).
No statistically significant differences were found in pos-
sible risk factors between patients with low BMD and
patients with a BMD within normal range (Table 3).
Fractures were described in 30 patients (16.4%), which is
significantly lower than the estimated age-standardised fracture
prevalence of 38.2% (P < .000) as described for England.27 Of
those patients who had experienced a fracture, 7 sustained
more than 1 fracture. There was insufficient data on which
fractures were fragility fractures. There was no significant dif-
ference in mean LBMD Z-score between patients with frac-
tures and patients without known fractures (P = .97).
4 | DISCUSSION
This multicentre study of BMD in adult ETPKU patients
shows that, although the mean BMD in ETPKU patients is
significantly lower compared to the general population,
BMD is within normal range in most patients. The preva-
lence of low BMD is at most observed at the lumbar spine in
5.5% of patients, which is lower than described in the meta-
analysis by Demirdas et al and other previous studies.7,8,10-13
This difference could be explained by the fact that most
studies included in the meta-analysis focused on a combina-
tion of both paediatric and adult PKU patients. Assessing
BMD in children is hampered by several factors and it is
known that low BMD might be overestimated in children
with a chronic illness.16,17 Also in the study of De Groot
et al, low BMD was described in only 6% of adult patients
while the percentage tended to be higher in children.7 The
only previous study which focused exclusively on BMD in
adult PKU patients, used other definitions (osteopenia and
osteoporosis; not according to the current ISCD definition)
but a Z-score ≤−2.5 was detected in 6.5%.15 In addition,
more recent studies that focused on BMD in both children
and adults found low BMD defined as Z-score ≤−2 in 4.5%
to 7.4% of the total group of PKU patients.28,29 As the pre-
sent study focuses on adults who are expected to have
achieved their peak bone mass,18 this is probably a more
reliable reflection of BMD in PKU.
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4.1 | Risk factors for low BMD
In our study population no risk factors for low BMD could
be identified. This is in agreement with other studies.8,15 The
prediction model described by Coakley et al, although based
on a small number of patients, found dietary factors like
compliance, medical food prescriptions, and vitamin D
intake to be of influence.28 In the present study, it was not
possible to draw conclusions on the exact amount of natural
protein intake and medical food protein but an association
with non-adherence to diet, low vitamin D concentration, or
vitamin D supplementation was not found. Some studies
show that deficiencies in essential fatty acids can be seen in
PKU, but there is limited evidence that this might be related
to BMD in PKU.29,30 Our study did not investigate this.
4.2 | Fracture risk
Fracture prevalence in our population was lower than the
age-standardised fracture prevalence as described for the
population of England.27 It is reasonable to consider that this
is more or less comparable with the prevalence of fractures
in Europe. The low fracture rate found in this study could be
explained by several reasons. Most importantly, in view of
the retrospective design of this study, the number of frac-
tures may have been underestimated. Other reasons might be
a difference in participation in high fracture risk activities
such as specific sports between ETPKU patients and the
general population27 which was not evaluated in this study.
Previous studies focusing on fractures in PKU reported a
comparable risk to the general population as well as a higher
fracture risk above age 8 detected in a very young group of
PKU patients measured by parent or self-report.29,31
BMD is not the only factor that determines the risk of
fractures, to assess the fracture probability in the general
population other risk factors should be taken into
account.14,19,20 The Fracture Risk Assesment Tool (Frax) is
available for fracture risk assessment above age 40 years.19
4.3 | Recommendations
Altogether, most ETPKU patients have a BMD within nor-
mal range, with only a maximum of 5.5% having a low
BMD. As mean BMD is lower compared to the general pop-
ulation, the prevalence of low BMD might be higher in PKU
patients >35-40 years of age, when bone mass is known to
decline.18
With the present data it can be argued that a DXA scan
should be requested in PKU patients who have an age
>35-40 years or in case of additional risk factors for frac-
tures like prolonged immobility, hypogonadism, chronic use
of steroids, malabsorption, alcohol abuse, previous fragility
fractures, or other conditions that cause an increased fracture
risk.14,18,19 The European PKU guideline advices (best prac-
tice based) to perform a first DXA scan in adolescence.3,4
Based on the present study it is a consideration to perform
the first DXA scan in a well regulated PKU patient without
further risk factors for fractures not in adolescence but at an
age >35-40 years.
4.4 | Strengths and limitations
The strength of the present study is the relatively large num-
ber patients, the fair proportion of patients with an age in
their fourth decade, and the participation of centres from dif-
ferent European countries, making the study population rep-
resentative of the European ETPKU population. In addition,
the study population included many patients with severe
PKU (based on Phe before start of treatment or natural pro-
tein intake).2-4
However, all patients were seen in a centre specialised in
PKU, making this a relatively well monitored population.
Therefore the results might not be applicable to less regu-
lated patients.
Most participating centres routinely performed a DXA
scan in all their patients, some centres only made a DXA
scan in a selection of patients. This might have caused bias
in the prevalence of low BMD. However, it is more likely
that only the patients who are thought to be at risk for low
BMD will be selected for a DXA scan. In that case, the
reported prevalence of low BMD is an overestimation.
Only the most recent DXA scans were selected for analy-
sis as BMD was thought to be more relevant in older
patients. It could be argued that in patients with multiple
DXA scans, a result of low BMD would result in a change
of treatment influencing the most recent DXA. However, no
factors of influence could be identified, making less likely
that interventions like vitamin D supplementation or a
change in diet directed by an earlier DXA scan resulted in
an improved BMD.
Due to the low prevalence of low BMD, the total number
of patients with low BMD was 10, hampering additional
analysis focusing on risk factors. Because of this small num-
ber a multiple regression model was not considered as a
most suitable test.
As dietary factors were derived from patient charts, the
data were not complete enough to draw conclusions on total
protein and medical food protein. Preferably dietary diaries
filled in by patients should be used to correlate BMD with
dietary factors.
The described fracture prevalence was based on chart
studies which are less reliable than an observational study or
assessment of patient reported fracture risk.
Although the study included some of the oldest ETPKU
patients >40 years of age, predictions on BMD in older age
256 LUBOUT ET AL.
cannot be made. As bone loss occurs with advancing age18,19
future studies in elderly, ETPKU patients are warranted to
assess how often low BMD is seen in advancing age and
whether these patients have an increased fracture risk.
5 | CONCLUSION
Mean BMD in early treated adult PKU patients is lower than
in the general population but the frequency of low BMD is
at maximum 5.5%. DXA scans should be done in well con-
trolled PKU patients >35-40 years of age and in those PKU
patients considered to be at increased risk for fractures.
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